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Abstract
Background: Genetic and epigenetic alterations in the GNAS locus are responsible for the Gsα protein dysfunctions
causing Pseudohypoparathyroidism (PHP) type Ia/c and Ib, respectively. For these heterogeneous diseases
characterized by multiple hormone resistances and Albright’s Hereditary Osteodystrophy (AHO) the current
classification results inadequate because of the clinical overlap between molecular subtypes and a standard clinical
approach is still missing.
In the present paper several members of the Study Group Endocrine diseases due to altered function of Gsα
protein of the Italian Society of Pediatric Endocrinology and Diabetology (ISPED) have reviewed and updated the
clinical-molecular data of the largest case series of (epi)/genetically characterized AHO/PHP patients; they then
produced a common healthcare pathway for patients with these disorders.
Methods: The molecular analysis of the GNAS gene and locus identified the causal alteration in 74 subjects (46
genetic and 28 epigenetic mutations). The clinical data at the diagnosis and their evolution during up to 15 years
follow-up were collected using two different cards.
Results: In patients with genetic mutations the growth impairment worsen during the time, while obesity
prevalence decreases; subcutaneous ossifications seem specific for this group. Brachydactyly has been detected in
half of the subjects with epigenetic alterations, in which the disease overts later in life, often with symptomatic
hypocalcaemia, and also early TSH and GHRH resistances have been recorded.
Conclusions: A dedicated healthcare pathway addressing all these aspects in a systematic way would improve the
clinical management, allowing an earlier recognition of some PHP features, the optimization of their medical
treatment and a better clinical-oriented molecular analysis. Furthermore, standardized follow-up data would provide
new insight into less known aspects.
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Background
Pseudohypoparathyroidism (PHP) defines a group of rare
heterogeneous metabolic disorders, characterized by re-
sistance to the peripheral action of PTH, the most import-
ant hormone regulating the calcium and phosphorus
homeostasis [1, 2]. Several mutations of the GNAS gene
(20q13.32) and epigenetic alterations within its locus have
been described as causes of the different forms of PHP
type I (i.e. PHP-Ia, PHP-Ib, PHP-Ic). They all induce an
impaired function of the Gsα protein (the α-subunit of the
heterotrimeric stimulatory G protein), which regulates the
adenylate cyclase activity in the signaling pathway of vari-
ous peptide hormones binding the G-protein-coupled
receptors (GPCR): PTH, TSH, GHRH, gonadotropins,
ACTH, and calcitonin among others [1, 3].
Inactivating mutations in exons 1–13 of the maternal
copy of the GNAS gene lead to PHP-Ia, whose phenotype
encompasses the Albright Hereditary Osteodystrophy
(AHO) signs including short stature (SS), brachydactyly
(BR), obesity (OB), round face (RF), subcutaneous ossifica-
tions (SO) and mental retardation (MR) together with
multiple resistances to PTH (rPTH), TSH (rTSH) and to
other aforementioned GPCR-binding hormones. Altered
response to other hormones (i.e. insulin) were recently
debated as part of the phenotype [4, 5]. In several subjects
with the same clinical features but normal Gsα protein in
vitro activity (i.e. PHP-Ic patients) mutations affecting the
C-term region of the GNAS gene and its binding site to
the GPCRs were described [6, 7]. A different form of the
disease, named Pseudopseudohypoparathyroidism (PPHP)
and characterized by isolated AHO features without hor-
mone resistances, occurs if germline mutations involve
the paternal copy of the gene [8]. PHP-Ia and PPHP may
affect members of the same family and such different clin-
ical presentation have been explained by tissue-specific
differential methylation patterns [9].
The PHP-Ib subgroup is classically defined by rPTH,
without AHO signs nor other hormone disruptions, except
at times rTSH [1]; and it is caused by epigenetic alterations
at the GNAS locus, that is one of the most complex ones
in the human genome. In addition to Gsα, it gives rise to
four other transcripts (XLαs, A/B, NESP55 and AS) [10]
whose expression is regulated by an imprinting mechanism
[11]. The loss of methylation on maternal exon A/B is the
most common alteration: in the familial autosomal domin-
ant form of the disease (i.e. AD-PHP-Ib) this involves dele-
tions in the STX16 gene, although in some families it was
also related to NESP55 and NESP-AS alterations [12, 13].
Conversely, the sporadic form of PHP-Ib shows multiple
alterations of the imprinting pattern (loss of methylation at
NESP-AS, XLαs, A/B and gain of methylation at NESP55);
paternal isodisomy of chromosome 20q involving the
GNAS locus has also been described in some patients with
large imprinting disruptions [14, 15].
In the last years several independent studies have re-
ported complex clinical phenotype encompassing AHO
features and multiple hormone resistances in patients
with molecular diagnosis of PHP-Ib, suggesting that
altered methylation may play a similar role to structural
mutations in the pathogenesis of the disease [16–19].
Conversely, in subjects with AHO and multihormone
resistances, with normal Gsα protein in vitro activity,
clinically indicated as having the PHP-Ic subtype, the
same alterations found in the GNAS locus have recently
been described [19]. Furthermore, GNAS gene mutations
were described also in patients with Progressive Osseous
Heteroplasia (POH) and primary Osteoma Cutis (OC)
broadening the spectrum of Gsα-related disorders and
representing two important differential diagnosis [20, 21].
Thus the clinical overlap between different genotypes
made the current classification inadequate pointing out
the need of an update.
On the other hand current literature data show a lack
of knowledge about some clinical features [22]: preva-
lence of several clinical signs are often debated, and to
date only few studies have considered the evolution of
the disease over the time. Likewise, due to the rareness
of the disease, a common clinical approach is still miss-
ing and no standards or recommendations are available
for the clinical routine.
In the largest series of PHP patients with a confirmed
molecular diagnosis this work attempts to describe the
genotype-phenotype correlation and to give a first insight
into the evolution of the disease in a mainly pediatric
population. To improve the standardization of the clinical
management and further data collection of PHP patients
we also introduce a possible flowchart for a common
healthcare pathway.
Methods
Patients
Since 1999, patients with clinical diagnosis of PHP,
defined as rPTH (i.e. raised serum PTH levels, in
presence of hyperphosphatemia and normo- or hypo-
calcaemia, despite normal renal function [16]) isolated
or associated to rTSH or AHO signs, were collected
countrywide by the main Italian referee Centers for
Pediatric Endocrinology within the research project
Molecular analysis of the GNAS gene in subjects with
suspected PHP of the Study Group Endocrine diseases
due to altered function of Gsα protein of the Italian
Society of Pediatric Endocrinology and Diabetology
(ISPED). DNA samples and clinical data were sent to
the Department of Public Health and Pediatrics of the
University of Turin, where the molecular analyses
were performed by searching for mutations within the
coding region and intron-exon boundaries of the
GNAS gene.
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In patients with wild-type GNAS sequence, the cooper-
ation of the Endocrinology Unit at Fondazione IRCCS Ca’
Granda Policlinico - University of Milan allowed to ex-
pand the molecular diagnosis by further methylation ana-
lysis on the GNAS locus.
The causal alteration was detected in a total of 74
subjects, from 69 unrelated families. The principal clin-
ical features and the molecular characterization of the
case series are presented in Tables 1, 2 and 3.
Structural mutations in exons 1–13 were detected in
42 subjects (4 couples of siblings), thus diagnosed as
PHP-Ia; in 4 patients (A17, A18, A45 and A46) the
phenotype was characterized by early and widespread
subcutaneous ossifications, raising a differential diagno-
sis with POH. Four other patients (A7, A12, A13 and
A40). 2 of them siblings, harbored the mutation affecting
the C-terminal region of the Gsα protein (exon 13),
associated to normal in vitro Gsa activity [6], allowing
the definition of the more rarely described PHP-Ic. The
pathogenicity of each variant was checked within the
1000 genomes database (www.internationalgenome.org)
and the mutation nomenclature within the Leiden Open
Variation Database (www.lovd.nl/3.0).
All 28 patients with epigenetic alterations in the GNAS
locus came from unrelated families. Altered methylation
patterns in multiple DMRs were detected in most of
them (n = 25, B1-25), allowing the diagnosis of sporadic
PHP-Ib. In the 3 remaining patients (B26-28) a deletion
on the STX16 gene responsible for the familial form of
the disease (AD-PHP-Ib) has been identified.
Clinical data at the time of the enrollment and during
the follow-up period were collected through 2 different
recording cards. The first one has been conceived to
assess the typical PHP signs, leading to the clinical suspi-
cion of the disease, i.e. the presence/absence of the AHO
signs and of PTH and TSH resistances; subsequently,
through a new research project, named Clinical Update
about patients with PHP/AHO a new follow-up card has
been drawn to collect further clinical details about pa-
tients with a confirmed molecular diagnosis. In particular
it has been focused on the evolution of auxological param-
eters, on the possible late onset of some AHO signs and
other hormone resistances, overall the less known ones.
This second part of the study is still going on in a clinical
network with the aim of taking care of the patients during
the whole pediatric age, and when possible also later in life
(through cooperation with adult age endocrinologists).
Informed consent was obtained for all patients in-
volved in the study from either parents (or legal
guardian), or from the patients themselves in case of
adults.
In the 2 cards, in addition to rPTH and the onset age,
rTSH was considered in presence of clinical or subclin-
ical hypothyroidism (i.e. high serum TSH, with or with-
out low serum level of free Thyroxine); other hormone
defects (resistances to GHRH (rGHRH), FSH/LH (rGn)
and reduced insulin sensitivity) were identified by
hormone increased basal levels or altered response to
the specific stimulation tests.
SS was diagnosed as height below the 3rd percentile
for chronological age, while OB was defined as Body
Mass Index (BMI) above the 97th percentile in children
(SDS ≥ 1.88) and above 30 kg/m2 in adults; overweight
(BMI ≥ 85th percentile or SDS ≥ 1.036 in children and
BMI ≥ 25 kg/m2 in adults) was also marked but not
considered for clinical diagnosis of PHP. The aforemen-
tioned auxological parameters have been evaluated
through the software Growth Calculator 3.0 (available
on the ISPED’s web site http://www.siedp.it/pagina/
151/growth+calculator+3) that gives access to several
growthcharts designed on different populations. Since
our patients had Italian origin, we employed the Italian
charts (INeS’ Charts and Cacciari’s Charts [23]) in order
to obtain uniformity.
BR was recorded if clinically present with positive
Archibald’s sign (in case of shortening of IV-V metacarpals)
and/or shown by the Metacarpophalangeal profile
(MPP, indicating at least one metacarpal bone or dis-
tal phalanx shorter than 2 SD score – SDS) [16]. SO
were reported if clinically evident or confirmed by X-rays;
in few patients bioptic analysis has been performed before
surgical removal.
RF was reported as clinical feature, while MR was
marked in case of psychomotor retardation or delayed
speech or need of assistant teacher and extra school help.
Molecular analysis
GNAS gene analysis
Genomic DNA was extracted from peripheral blood
leukocytes using the commercial kit PUREGENE® DNA
Purification Kit, Gentra. The 13 coding exons of the
GNAS gene, together with the exon-intron boundaries
regions were amplified by PCR using the ABI PRISM®
BigDye Terminator Cycle Sequencing Kit and then
Table 1 Principal features at diagnosis in the 2 groups of patients with GNAS gene mutations and GNAS locus altered methylation
N° Subjects Sex: F/M Age Ca (mEq/l) P (mg/dl) PTH (pg/ml) TSH (μU/ml)
Gene mutation 46 29/17 4.8 (0.1–23.4) 4.3 (2.25–6.7) 6.8 (4–12.2) 308 (15.6–1200) 7.8 (1.6–22.1)
Locus altered methylation 28 16/12 10.5 (0.5–65) 3.6 (1.9–9.2) 6.9 (3.6–10.5) 358 (128–1532) 5 (3.36–8.95)
Legend. Sex: Females/Males; Age: median age in years (range); Ca: median total serum Calcium levels (range); P: median serum Phosphate level (range); PTH:
median serum PTH (range); TSH: median serum TSH level (range)
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Table 2 Clinical features and molecular characterization of patients with GNAS gene mutations
Pt Sex Age AHO signs Hormone resistances GNAS gene mutation
A1 F 0.25 OB rPTH, rTSH c.240 + 1G > T
A2 F 2 BR, SO, MR, (OB), RF rPTH, rTSH (12) c.347_348insC
A3 M 3.68 BR, MR, OB, RF rPTH, rTSH c.347_348insT
A4 F 1.53 BR, SS, (OB), RF rPTH, rTSH c.1009C > T
A5 F 3.31 BR*, MR, OB, RF rPTH, rTSH c.421_422del
A6 M 4.72 BR, SO, MR, (OB/OW), RF rPTH, rTSH c.112delC
A7 F 5.8 BR*, SS (6.8), OB/OW, RF rPTH, rTSH c.1177G > T
A8 F 7.19 BR, SO (13), OB/OW (10.7), RF rPTH, rTSH c.348C > T
A9 M 23.17 BR, MR, SS rTSH, rFSH/LH c.478G > A
A10 F 0.95 SO, OB, RF rPTH, rTSH c.1009C > T
A11 M 8.2 BR, SO, MR, SS, RF rPTH, rTSH, rFSH/LH c.103C > T
A12 F 12.73 BR, OB/OW, RF rPTH, rTSH c.1177G > T
A13 M 12.72 SS, RF rPTH, rTSH c.1177G > T
A14 F 4.45 BR, SO, MR, RF rPTH, rTSH, rFSH/LH c.523_524del
A15 M 4.45 BR, SO, MR, SS, OB/OW, RF rPTH, rTSH c.523_524del
A16 M 6.2 SO, MR rPTH, rTSH c.212 + 2_212 + 6del
A17 F 2 BR (10.3), SO, (OB) rPTH, rTSH, rGHRH (10.3) c.103C > T
A18 F 23.41 BR, SO, MR, OB, RF rPTH, rTSH c.103C > T
A19 F 7.2 BR rPTH, rTSH c.742G > C
A20 F 10.47 BR, OB/OW rPTH, rTSH c.742G > C
A21 M 11.01 BR, SS, OB, RF rPTH, rTSH, rLH/FSH c.1009C > T
A22 M 2 BR* (8), SO, MR, OB (0.5), RF(11) rTSH, rPTH (8) c.521_522del
A23 M 11.23 BR, MR, OB/OW, RF rPTH, rTSH c.805A > G
A24 M 10.1 BR, SO, MR, RF rPTH, rTSH c.568_571del
A25 F 9.75 BR, MR, SS, OB/OW, RF rPTH, rTSH, rFSH/LH rIns c.91C > T
A26 F 1.5 BR, SO, MR, OB, RF rPTH, rTSH, rIns c.91C > T
A27 F 1.5 SO, RF rPTH, rTSH c.568_571del
A28 F 4.6 BR, SO, MR, SS, OB/OW, RF rPTH, rTSH c.568_571del
A29 M 1.3 MR, OB, RF rPTH, rTSH c.568_571del
A30 M 1.3 BR, MR (2.8), SS, (OB), RF rPTH (2.8), rTSH, rGHRH c.21dupT
A31 F 1.54 SO, MR, OB/OW, RF rTSH (1.9), rPTH (4) c.347_348insT
A32 F 8.86 BR, MR, OB, RF rPTH, rTSH c.481C > T
A33 F 8.43 BR, MR, RF rPTH, rTSH c.568_571del
A34 F 14 BR, MR, SS, OB/OW, RF rPTH, rTSH c.728C > T
A35 M 12.77 BR, SO rPTH, rTSH c.110del
A36 F 16.8 BR, SO, MR, OB/OW, RF rPTH, rTSH c.1021_1022ins23nt
A37 F 4.89 BR*, MR, OB, RF rPTH, rTSH c.863_864del
A38 F 3.56 BR, SO, SS, OB/OW, FR rPTH, rTSH c.87dupA
A39 F 0.1 BR, SO, MR, (OB 0.1), RF rPTH, rTSH, c.568_571del
A40 F 0.94 BR*, SS, (OB/OW), RF rPTH c.1177G > A
A41 M 2.32 BR, SO, OB/OW, RF rPTH, c.347_348insC
A42 F 13.86 BR, MR, RF rTSH c.97G > A
A43 F 0.91 BR, MR, SS, OB, RF rPTH, rTSH c.363_364del
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directly sequenceed by using the ABI PRISM® Genetic
Analyzer 3100 (Applied Biosystems, Foster City, CA).
Each mutation has been searched for and excluded in
50 control subjects as previously described [16]. For
few mutations in vitro mutant expression has been
tested [6].
Methylation analysis of GNAS locus and detection of STX
deletions
GNAS DMRs methylation status was assessed both by
combined bisulfite restriction analysis and methylation
specific-multiplex ligand-dependent probe amplification
(MS-MLPA). The presence of STX16 gene deletions was
Table 2 Clinical features and molecular characterization of patients with GNAS gene mutations (Continued)
A44 F 14.38 BR, SS – c.568_571del
A45 M 14.15 BR, SO rPTH c.103C > T
A46 M 6.61 SO, OB/OW (9.11) rPTH c.103C > T
Features that occurred prior to the first diagnosis or later in life are remarked in bulk and the corresponding age is noticed in parenthesis. Features that were present at
the diagnosis but disappeared later in life are reported in parenthesis. A12 + A13; A14 + A15; A19 + A20; A25 + A26; A45 + A46 are couple of brothers and/or sisters
Table 3 Clinical features and molecular characterization of patients with GNAS locus altered methylation
Case Sex Age AHO signs Hormone resistances GNAS locus methylation alteration
B1 M 6.9 BR, MR, RF rPTH, rTSH (11) AB/NESP/AS/XL
B2 M 11.43 MR (3.5), RF rPTH AB/NESP/AS/XL
B3 F 7.5 – rPTH AB/NESP/AS/XL
B4 F 65 BR, OB, RF rPTH, rLH/FSH AB/NESP/AS/XL
B5 F 5.2 MR, OB/OW, RF rPTH, rTSH AB/NESP/AS/XL
B6 F 9.95 RF rPTH AB/NESP/AS/XL
B7 M 15 BR rPTH AB/NESP/AS/XL
B8 F 13.26 – rPTH AB/NESP/AS/XL
B9 M 12.13 – rPTH AB/NESP/AS/XL
B10 F 6.55 MR, OB/OW rPTH, rTSH AB/NESP/AS/XL
B11 M 10.5 BR, OB/OW, RF rPTH AB/NESP/AS/XL
B12 M 37.5 BR, SS,OB/OW, RF rPTH AB/NESP/AS/XL
B13 F 9 RF rPTH AB/NESP/AS/XL
B14 F 0.5 OB/OW, RF rPTH, rTSH AB/NESP/AS/XL
B15 M 12.76 RF rPTH AB/NESP/AS/XL
B16 M 12.23 BR rPTH AB/NESP/AS/XL
B17 M 12 BR, OB, RF rPTH, rTSH AB/NESP/AS/XL
B18 M 16 BR*, OB/OW, RF rPTH, rGHRH AB/NESP/AS/XL
B19 F 4 BR*, OB/OW, RF rPTH, rTSH AB/NESP/AS/XL
B20 F 4.16 MR, OB/OW, RF rPTH, rTSH AB/NESP/AS/XL
B21 F 10.09 RF rPTH, rTSH AB/NESP/AS/XL
B22 F 7,41 BR rPTH AB/NESP/AS/XL
B23 F 5.5 BR, MR, RF rPTH AB/NESP/AS/XL
B24 F 23.5 BR, MR rPTH AB/NESP/AS/XL
B25 F 3.06 BR rPTH, rTSH (6) AB/NESP/AS/XL
B26 M 29 BR*, OB/OW rPTH Del at STX16 gene
B27 M 12.9 – rPTH Del at STX16 gene
B28 F 19.6 SS, OB/OW, RF rPTH Del at STX16 gene
Sex: Female (F), Male (M); Age: age at diagnosis or at first evaluation, expressed in years; AHO signs: brachydactyly (BR, in case of X-Ray study: BR*), subcutaneous
ossifications (SO), mental retardation (MR), short stature (SS), obesity and overweight (OB/OW), round face (RF); Hormone resistances: PTH resistance (rPTH), TSH
resistance (rTSH), FSH/LH resistance (rFSH/LH), GHRH resistance (rGHRH), Insulin resistance (rIns). Features that occurred prior to the first diagnosis or later in life
are remarked in bulk and the corresponding age is noticed in parenthesis. Features that were present at the diagnosis but disappeared later in life are reported
in parenthesis. A12 + A13; A14 + A15; A19 + A20; A25 + A26; A45 + A46 are couple of brothers and/or sisters
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investigated by multiplex PCR and MS-MLPA, as previ-
ously described [8, 16, 24].
Statistical analysis
To explore the relationship among clinical features and
molecular diagnosis we used the Mann–Whitney U and
Fisher nonparametric tests, available as open access tools
on the VassarStats: Website for Statistical Computation
(http://vassarstats.net). A two-tailed P value of <0.05 was
considered statistically significant and results are pre-
sented as median value and range.
Results
The two groups of patients differ in the age of onset of
the disease (p < 0.001): patients with genetic mutations
came to medical attention at a median age of 4.8 years
(range 0.1–23.4) and in 29/46 cases (63%) the reasons
for consultation were AHO signs (early-onset obesity,
delayed growth, heterotopic ossifications) and/or hormo-
nal alterations (overall hypothyroidism); 4/46 patients
only showed symptomatic hypocalcaemia as first sign.
Conversely, patients with locus alterations were older at
diagnosis (median age 10.5 years; range 0.5–65), most of
them (n = 20/28, 70%) presenting with seizures, tetany,
and positive Trousseau’s sign.
Clinical data prevalence in the studied series is resumed
in Fig. 1: PTH resistance was detected in most patients
with genetic mutations (n = 43/46, 93%) at a median age
of 5 years (range 0.9–23.4), while all patients with imprint-
ing alterations showed rPTH at diagnosis, often occurring
later in life (median age 11.6 years; range 0.5– 65), with
symptomatic hypocalcaemia. TSH resistance arose in 43/
46 patients (93%) with genetic mutations at median age of
5.8 years (range 0.25–23.4) and in 9/28 patients (32%)
with imprinting alterations at median age of 6.28 years
(range 0.5–11).
Other hormone resistances were reported in 8/46 pa-
tients with genetic mutations (17%) only, but notably 44
of the total case series were younger than 12 years at the
time of last evaluation. Gonadotropins resistance was re-
corded in 5 patients, associated to insulin resistance in
one of them (A26), which is the further isolated hormonal
resistance in her sister (A25). GH defect was detected at
diagnosis in 2 patients: A30 (1.3 and 5 years old at diagno-
sis and follow-up, respectively) showed short stature and a
lack of response to the GHRH+Arginine test but a
second test was not performed because his height velocity
(HV) has improved; and A17 (2 and 10.3 years old at diag-
nosis and follow-up, respectively), displayed GH deficiency
after two stimulation tests. Therefore she underwent a
treatment with hrGH with HV improvement and
normalization of the height to target height.
Among patients with epimutations, in one patient
(B18) only GHRH resistance has been reported, occur-
ring in adult age; for a female patient (B4) hypofertility
was referred when she was 29, but she came late to
medical observation with incidental diagnosis of hypo-
calcaemia as possible sign of mild hormonal alteration.
Auxological evaluations were obtained (Fig. 2) in 44/46
patients with genetic mutations and SS became evident in
15 subjects (34%) at a median age of 6.8 years (range
0.91–23.17); 11 of them were still pre-pubertal at the time
of the examination (<12 years). Auxological data were
available for 23/28 subjects with imprinting alterations
and 2 of them (9%) were short at the time of enrollment.
Weight excess was recorded in 32/44 patients with gen-
etic mutations (73%) and it encompassed either early-onset
obesity (n = 19, 43%) with a median age of 1.5 years (range
0.9–23.4), or overweight (n = 13, 30%) later (median age
10.1 years, range 1.5–19.5). Most patients (n = 28) with
weight excess were pre-pubertal (<12 years) at the time of
the evaluation. Only 2/23 subjects with imprinting alter-
ations (9%) showed overt obesity at extremely different
Fig. 1 Prevalence of AHO signs and hormone resistances in the 2 group of patients with GNAS gene mutations (dark grey bars) and GNAS locus
mutations (light grey bars): encompassing brachydactyly (BR) (p- value 0.002), subcutaneous ossifications (SO), mental retardation (MR) (p value
0.008), short stature (SS) (p value 0.04), obesity and overweight (OB/OW) (p value 0.16), round face (RF) (p value 0.18), PTH resistance (rPTH), TSH
resistance (rTSH) (p value <0.0001), other hormone resistances (HR) (p value 0.37)
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ages (1.2 and 65 years); while 10/23 further patients (43%)
were overweight (median age 14.4 years, range 4.2–37.5).
Follow-up data in 13 patients with genetic mutations
(Fig. 3) demonstrated an evolution of the auxological
parameters over the time: during a mean follow-up time of
6.2 years, SS prevalence increased from 31% (median age
1.4 years, range 0.94–8.2) to 38% (median age 10.1 years,
range 5.04–17.1), while weight excess prevalence decreased
Fig. 2 a Prevalence of short (black bars) compared to normal stature (white bars), between the 2 groups of patients with GNAS gene mutations
(named “Mutations”) and GNAS locus imprinting alterations (named “Epimutations”). b Prevalence of weight excess (overt obesity: black;
overweight: grey) compared to normal weight (white) at the time of enrollment between two groups with GNAS gene mutations (named
“Mutations”) anf GNAS locus imprinting alterations (named “Epimutations”). c and d: Heights of the presented case series at the time of
enrollment on females (section c) and males growth chart (section d); patients with GNAS gene mutations are presented by blue plots and those
with GNAS locus imprinting alterations by yellow plots
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from 77 to 54%. At the time of enrollment 10 very young
patients (oldest age 5.8 years) showed weight excess: at
follow-up half of them normalized or strongly reduced the
weight at a median age of 12.5 years (range 5.6–
24.35), while the remaining 5 patients were still obese
or overweight (median age 5.0 years, range 2.2–11.2).
For all patients, hypocaloric regimens for age and rec-
ommendations aimed to increase the physical activity
Fig. 3 Height (plot a) and Weight (plot b) auxological data of 13 patients with GNAS gene mutations at follow-up: data are presented as Standars
Deviation Score (SDS) calculated on age-adapted growth charts vs. age in years (AGES)
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over the time were the only reported therapeutic ap-
proaches, without clarification about any further spe-
cific treatment.
BR has been identified in 39/46 subjects with genetic
mutations (85%) at a median age of 7.2 years (range 0.9–
23.4), while the sign was positive in 14/28 subjects with
imprinting alterations (50%, p = 0.002) and recorded at a
later median age of 13.2 years (range 1.2–65; p < 0.001).
None of the latter showed SO, which were detected in
23/46 subjects harboring genetic mutations (50%), at a
median age of 4.5 years (range 1.5–23.4). Interestingly,
9/11 (82%) patients with exon 1 mutations showed SO,
which were present in 14/35 (40%) patients only harbor-
ing mutations throughout the remaining GNAS coding
region. Signs of MR were more often observed among
mutated than epimutated patients (in 26 and 7 patients
respectively, 57 and 25%, p = 0.008), but the age at pres-
entation didn’t show any statistical difference (median
age was 4.75 years in both groups). Few information
were available about the features of the cognitive impair-
ment: among patients with genetic mutations it involved
psychomotor (n = 4) or speech delay (n = 4), school
problems with need of extra help (n = 2), and a slight
global retardation of developmental milestones (n = 5);
results of objective cognitive tests were available for 5
patients.
The review and update of clinical data of this country-
wide collected cohort of patients with confirmed mo-
lecular diagnosis of PHP has led us to develop two flow-
charts, one for the initial diagnosis and the other for the
monitoring of the disease, as common tool for the clin-
ical routine management of these subjects (Fig. 4).
Discussion
The present study reports the clinical review and update
about the largest cohort of patients with a confirmed
molecular diagnosis of PHP, in order to propose a com-
mon standard of care. Due to the rarity of the disease
and to the overlapping phenotype among patients with
different genotypes we think that initially it may be more
useful to organize the clinical management and follow-
up of PHP patients in a unique scheme, independently
of their genotype. This approach will possibly help in de-
tecting (and treating) clinical features earlier during the
history of the disease. The adoption of a common
healthcare pathway will allow the collection of standard-
ized data that may improve the further characterization
of the disease, including more precise information about
the phenotype/genotype correlation, and the success of
treatments.
Similar to previous reports [25, 26] our patients
showed a bimodal way of presentation: younger pediatric
subjects seeking for medical advice because of early-
onset obesity and/or congenital hypothyroidism had
more often structural gene mutations, suggesting a more
severe impairment of the Gsα protein, not only in endo-
crine organs as reported by prior functional studies [27],
but probably also in adipose tissue. Conversely, symp-
tomatic hypocalcaemia is the most often presentation in
peripubertal and older patients harboring locus imprint-
ing alterations: this genotype might induce a slight im-
pairment of the Gsα activity which, thank to a higher
production of PTH, would preserve normocalcaemia
until puberty or even adulthood, when the increased cal-
cium requirement makes the resistance clinically evi-
dent. As regard to rPTH it is nowadays debated how
long-term elevated PTH and calcium substitution might
interfere on bone health status and BMD [28]: a focused
monitoring of calcium/phosphorus metabolism and min-
eral bone status, also considering the different treatment
regimens adopted over the time, might produce more
uniform data to gain some new insight into these issues
for patients with both genotypes.
Often described as subclinical hypothyroidism [22],
rTSH was confirmed as the second most common hor-
mone derangement [29, 30]. Its congenital or early onset
in patients with either genetic or epigenetic mutations
suggests that it should be searched for at diagnosis in
both PHP subtypes; furthermore this finding seems to
indicate a greater sensitivity to the Gsα altered pathway
in thyroid than in parathyroid cells [26]. In order to de-
fine common clinical approaches, standardized follow-
up studies are required to assess the optimal TSH-cut-
off (TSH 5–10 μU/ml) at which substitutive treatment
should be started, its duration until or after the growth
has been completed and the timing of TSH levels
monitoring.
Although multiple hormone resistances were classic-
ally described in PHP-Ia patients [1], their relative low
prevalence in our series could in part be explained by
the very young age of most subjects, but it also might re-
flect that neither the historically reported hormonal de-
rangements (involving vasopressin, prolactin, ACTH,
CRF, calcitonin and glucagon [31–33]) nor the newly
recognized ones (including insulin, leptin and αMSH
[5]) are initially investigated and routinely included in
the follow-up program. Likewise for rGHRH, reported as
a common finding in PHP-Ia subjects, the GH secretory
testing should be part of the initial management [22,
34]. A prompt diagnosis of GH deficiency as soon as
height velocity decreases, would allow an early replace-
ment treatment overall before the typically observed pre-
mature fusion of growth plates hampers the pubertal
growth spurt. Controlled trials enrolling large series of
genetically and clinically characterized PHP-Ia subjects
would be necessary to clarify the correct rhGH dosage,
the duration of treatment and the eventual combination
with GnRH analogs [35].
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The evidence of rGHRH in a patient with altered
methylation further confirms [26] the possible onset of
GH deficiency also in PHP-Ib subgroup of patients and
indicates the need of more investigations to assess its
prevalence and the correct management in this subtype.
As regards to the AHO signs, among patients with
genetic mutations evolutive trends have been evidenced
for both SS and OB: the increasing prevalence of SS over
the time strengthen the need of a standardized early
diagnosis and treatment not only of rGHRH but also of
other hormonal derangements that may have an impact
on the final stature of these subjects [35]. Conversely,
early weight excess, overall OB, supports the hypothesis
that an abnormal function of the melanocortin-4 recep-
tors, impairing energy expenditure and insulin sensitivity
and inducing early hyperphagia [5, 36], might be respon-
sible for fat accumulation since infancy. The fact that
weight excess becomes milder might suggest that other
factors influence the energy intake and expenditure, as
well as the body composition over the time. The treat-
ment of OB and OW in these patients has been so far
limited to suggestions for a balanced nutrition and regu-
lar body-exercise; thus, the lack of common standards
made the therapeutic approach often inhomogeneous.
The inclusion of low-calories and low-fat dietary regi-
mens, the indication of regular physical activity over the
time and the development of nutritional education pro-
grams as part of the therapeutic approach in these
patients and their families will probably help in reducing
their metabolic impairment. The feasibility of physical
pharmacological treatment to reduce the caloric intake
may be evaluated as alternative if dietary approach is
unsuccessfully. The possibility to share standardized data
searching for insulin resistance in large series would also
indicate the correct follow-up and a specific therapeutic
approach in those subjects with hormonal derangement.
Furthermore, it is important to stress that OB and OW
may be related to hormonal impairments but also to a
different eating behavior, overall during the evolutive
age: standardized endocrinological and psychological
follow-up should help clarifying which of them might
impact more on fat accumulation.
In this regard, data on mental retardation are still
limited; our study further confirms the heterogeneity of
the cognitive areas involved in the delay [22] and
underlines the need of objective standard tests to verify
the most involved areas, also recording the possible evo-
lution of the retardation over the time. Parallel to the
evaluation of the straight cognitive impairment, the
recent approach to pediatric MR should include stand-
ard tests assessing coping skills and adaptive behaviors,
which play a central role in how the delay impacts on
the daily and social life of the patients [37, 38]. The
presence of the sign also in a substantial fraction of
patients with imprinting alterations may suggest that
even mild reduction in Gsa function, might interfere
with the neuronal activity affecting the normal devel-
opment milestones.
BR is one of the most typical sign of PHP-Ia; its preva-
lence lower than 100% among subjects with genetic
mutations may be explained by their young age (below
to the indicated cut-off age of 5 years [39]), and also by
the fact that the MPP hasn’t been performed in all
subjects, thus potentially underdiagnosing the milder
bone alterations. The new prevalence data of 50% among
epimutated patients, raises the question if even a slight
reduction in Gsα activity might produce specific alter-
ations in hand bone growth: comparative studies are
needed to define if it involves the same pattern as in
mutated patients.
The only alterations that seem to be specific for
genetic mutations are SO, since our series confirms
their complete absence in case of locus anomalies
[26]. The higher percentage of exon 1 and frameshift
mutations among patients showing SO might prove its
pathogenetic role as unique one encoding exclusively
for Gsα [8]. The young median age of presentation
and recent reports indicating possible progression
patterns suggests to monitor their evolution in num-
ber, size and depth with systematic body-mapping
during the follow-up, also in order to differentiate this
sign from POH.
Conclusions
In conclusion, PHP is indeed a very heterogeneous
disease, deeply investigated at molecular level in the
last decade, for which several clinical aspects have
still to be defined in details. Facing its rarity and
complexity the ISPED’s Study Group developed the
two flow-charts presented in the present paper as
(See figure on previous page.)
Fig. 4 Diagnostic (a) and follow-up (b) flowcharts for patients with suspected PHP. a In the initial diagnostic phase we suggest to assess the presence
or absence of each AHO sign and hormone resistance possibly involved in PHP through targeted clinical examinations (physical and neuropsychiatric),
laboratory tests (on blood and urine) and medical imaging investigations. This wide diagnostic approach, despite laborious, represents an exhaustive
base-line assessment for later comparative examinations. b During the follow-up management we propose for each clinical feature involved in PHP a
practical checklist of clinical, biochemical and/or imaging investigations to perform periodically or in case of symptoms in the follow-up of PHP
patients. In particular, we believe that patients who are very young at diagnosis would benefit of systematic reevaluations, in order to correctly
manage late complications of the disease and to detect late-onset signs during the growth for a prompt treatment
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diagnostic and therapeutic tool for clinical routine pur-
pose. The proposed pathways should certainly be vali-
dated on a larger cohort before their publication as
official suggestions or guidelines, but meanwhile, they
may be used as standardized schemes in order to
obtain uniform clinical data for further studies in the
PHP/AHO population.
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